Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | GALR2 | O43603 | 1/20 | 0.37 |
| ▸ | GALR1 | P47211 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505762 | 0.91 | GALR2 (0.40) | MAPK1BRAFNPY5RCYP2D6CYP2C9 | |
| SCHEMBL10010866 | 0.91 | MAPK1 (0.46) | MAPK1BRAFNPY5RCYP2D6CYP2C9 | |
| SCHEMBL10009161 | 0.90 | MAPK1 (0.50) | MAPK1BRAFNPY5RCYP2D6CYP2C9 | |
| SCHEMBL1506340 | 0.90 | CYP2D6 (0.46) | MAPK1BRAFNPY5RCYP2D6CYP2C9 | |
| SCHEMBL1506469 | 0.89 | MAPK1 (0.46) | MAPK1BRAFNPY5RCYP2D6CYP2C9 | |
| SCHEMBL10010154 | 0.88 | MAPK1 (0.44) | MAPK1BRAFNPY5RCYP2D6CYP2C9 | |
| SCHEMBL1506163 | 0.87 | THRB (0.45) | MAPK1GPR52 | |
| SCHEMBL10008365 | 0.87 | MAPK1 (0.43) | MAPK1BRAFNPY5RCYP2D6CYP2C9 | |
| SCHEMBL1506242 | 0.86 | MAPK1 (0.46) | MAPK1BRAFNPY5RCYP2D6CYP2C9 | |
| SCHEMBL10009879 | 0.84 | MAPK1 (0.45) | MAPK1BRAFNPY5RCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574832-B | Substituted N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | disclosed |
| US-8791144-B2 | Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| EP-2491024-B1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | disclosed |
| EP-2491024-A1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| CN-102574832-A | Substituted N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV | 2012-07-11 | — | — | CN | disclosed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | disclosed |
| WO-2011033018-A1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | CHRM1, CHRNA1, CHRM3 | MAPK1 1404/4885BRAF 3496/4885NPY5R 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.